CSIMarket
 


Kamada Ltd   (KMDA)
Other Ticker:  
 

Kamada Ltd 's Quick Ratio

KMDA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the forth quarter 2023, Quick Ratio deteriorated to 1.12 below Kamada Ltd 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 91 other companies have achieved higher Quick Ratio than Kamada Ltd in forth quarter 2023. While Quick Ratio total ranking in the forth quarter 2023 has deteriorated compared to the prior quarter from 0 to 682.

Explain Quick Ratio?
How much Cash & cash equivalents KMDA´s has?
What are KMDA´s Current Liabilities?


KMDA Quick Ratio (Dec 31 2023)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Change -34.49 % -34.49 % -34.49 % -34.49 % 40.05 %
Y / Y Cash & cash equivalent Change 62.42 % 62.42 % 62.42 % 62.42 % 84.31 %
Quick Ratio MRQ 1.12 1.12 1.12 1.12 0.45
KMDA's Total Ranking # 682 # 0 # 0 # 3164 #
Seq. Current Liabilities Change 0 % 0 % 0 % -34.49 % 0 %
Seq. Cash & cash equivalent Change 0 % 0 % 0 % 62.42 % 0 %



Quick Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 92
Healthcare Sector # 189
Overall Market # 682


Quick Ratio Statistics
High Average Low
2.81 1.21 0.34
(Dec 31 2020)   (Dec 31 2021)




Financial Statements
Kamada Ltd 's Current Liabilities $ 50 Millions Visit KMDA's Balance sheet
Kamada Ltd 's Cash & cash equivalent $ 56 Millions Visit KMDA's Balance sheet
Source of KMDA's Sales Visit KMDA's Sales by Geography


Cumulative Kamada Ltd 's Quick Ratio

KMDA's Quick Ratio for the trailling 12 Months

KMDA Quick Ratio

(Dec 31 2023)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities TTM Growth -34.49 % -34.49 % -34.49 % -34.49 % 40.05 %
Y / Y Cash & cash equivalent TTM Growth 62.42 % 62.42 % 62.42 % 62.42 % 84.31 %
Quick Ratio TTM 1.12 0.9 0.72 0.57 0.45
Total Ranking TTM # 1746 # 0 # 0 # 1574 #
Seq. Current Liabilities TTM Growth 0 % 0 % 0 % -34.49 % 0 %
Seq. Cash & cash equivalent TTM Growth 0 % 0 % 0 % 62.42 % 0 %


On the trailing twelve months basis KMDA Cash & cash equivalent soared by 62.42 % in IV Quarter 2023 year on year, while Current Liabilities remained unchanged to $50 millions, this led to increase in in Kamada Ltd 's Quick Ratio to 1.12, Quick Ratio remained below KMDA average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 143 other companies have achieved higher Quick Ratio than Kamada Ltd . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2023 from 0 to 1746.

Explain Quick Ratio?
How much Cash & cash equivalents KMDA´s has?
What are KMDA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 144
Healthcare Sector # 327
Within the Market # 1746


trailing twelve months Quick Ratio Statistics
High Average Low
2.81 1.22 0.34
(Dec 31 2020)   (Dec 31 2021)




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Revance Therapeutics Inc   2.85 $ 254.465  Millions$ 89.224  Millions
Hookipa Pharma inc   2.79 $ 117.096  Millions$ 41.988  Millions
G1 Therapeutics Inc   2.76 $ 82.156  Millions$ 29.716  Millions
Mersana Therapeutics Inc   2.74 $ 174.561  Millions$ 63.637  Millions
Precigen Inc   2.73 $ 62.855  Millions$ 22.985  Millions
Arrowhead Pharmaceuticals Inc   2.69 $ 162.064  Millions$ 60.302  Millions
Paxmedica Inc   2.62 $ 4.711  Millions$ 1.795  Millions
Alnylam Pharmaceuticals Inc   2.51 $ 2,428.204  Millions$ 967.786  Millions
Acurx Pharmaceuticals inc   2.46 $ 7.474  Millions$ 3.042  Millions
Bioxcel Therapeutics Inc   2.39 $ 65.221  Millions$ 27.267  Millions
Avidity Biosciences Inc   2.29 $ 185.082  Millions$ 80.680  Millions
Hutchmed china Limited  2.20 $ 886.336  Millions$ 403.027  Millions
Insmed Inc  2.11 $ 780.447  Millions$ 370.021  Millions
Talphera Inc   2.08 $ 9.381  Millions$ 4.512  Millions
Cara Therapeutics inc   2.02 $ 51.775  Millions$ 25.592  Millions
Ampio Pharmaceuticals inc   1.95 $ 4.089  Millions$ 2.102  Millions
Nextcure Inc   1.90 $ 13.082  Millions$ 6.883  Millions
Immunic Inc   1.89 $ 46.674  Millions$ 24.729  Millions
Catalyst Pharmaceuticals Inc   1.81 $ 137.636  Millions$ 76.063  Millions
Macrogenics Inc   1.80 $ 100.956  Millions$ 56.108  Millions
Beigene ltd   1.76 $ 3,183.273  Millions$ 1,810.113  Millions
Endo International Plc  1.76 $ 945.621  Millions$ 538.794  Millions
Eterna Therapeutics Inc   1.74 $ 7.575  Millions$ 4.357  Millions
Vaxxinity Inc   1.73 $ 30.395  Millions$ 17.605  Millions
Amicus Therapeutics inc   1.71 $ 286.200  Millions$ 167.689  Millions
23andme Holding Co  1.68 $ 242.418  Millions$ 144.139  Millions
Eyenovia inc   1.56 $ 14.851  Millions$ 9.530  Millions
Kiora Pharmaceuticals Inc  1.55 $ 2.455  Millions$ 1.587  Millions
Ani Pharmaceuticals Inc  1.52 $ 221.121  Millions$ 145.477  Millions
Avenue Therapeutics Inc   1.49 $ 1.783  Millions$ 1.196  Millions

Date modified: 2024-03-08T06:20:17+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com